[1]

[2]

SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.

[3]

LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.

[4]

YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.

[5]

XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.

[6]

CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.

[7]

. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.

[8]

. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.

[9]

[10]

YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.

[11]

DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.

[12]

GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.

[13]

. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.

[14]

. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.

[15]

. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

参数	筛查人数（例）	高危人数（例）	确诊（例）	阳性预测值（%）	检出率（%）	假阳性率（%）
Wald 1988	49 226	3 593	21	0.58	68	7.3
SURUSS 2003	49 226	6 350	25	0.39	80	12.9

参数	筛查人数（例）	高危人数（例）	确诊（例）	阳性预测值（%）	检出率（%）	假阳性率（%）
Wald 1988	49 226	3 593	21	0.58	68	7.3
SURUSS 2003	49 226	6 350	25	0.39	80	12.9

1	周建军,胡娅莉. 唐氏综合征的中孕期筛查[J].中国实用妇科与产科杂志,2008,24(2):90-93.
2	沈凤贤,赵丽,吕时铭,等.中孕期唐氏综合征产前筛查的质量管理[J]. 中华检验医学杂志,2014,37(11):870-875.
3	中华人民共和国卫生部. WS 322.1-2010 中华人民共和国卫生行业标准[S].北京:中国标准出版社,2010.
4	WALD NJ,RODECK C,HACKSHAW AK,et al.SURUSS in perspective[J]. BJOG,2004,111(6):521-531.
5	WILSON KL,CZERWINSKI JL,HOSKOVEC JM,et al.NSGC practice guideline:prenatal screening and diagnostic testing options for chromosome aneuploidy[J]. J Genet Couns, 2013,22(1):4-15.
6	HIXSON L,GOEL S,SCHUBER P,et al.An overview on prenatal screening for chromosomal aberrations[J]. J Lab Autom,2015,20(5):562-573.

RichHTML

PDF (PC)